IP Library › Granted Patent US 12,433,878
Granted Patent B2
US 12,433,878 · App. 18/171,831 · Granted Oct 7, 2025

Uses of bupivacaine multivesicular liposomes as stellate ganglion block

Inventors: Roy Winston (Tampa, FL); Jared Ham (Severn, MD); Jonathan Slonin (Palm City, FL)
Assignee: Pacira Pharmaceuticals, Inc.
A61K31/445A61K9/0019A61P23/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,433,878
App. No.
18/171,831
Granted
Oct 7, 2025
Kind
B2
Abstract

Embodiments of the present disclosure relate to the use of bupivacaine multivesicular liposomes (MVLs) as stellate ganglion block (SGB) for treating or ameliorating various diseases and conditions, including but not limited to cardiac electrical storm or cardiac arrythmia/dysrhythmia following heart surgery.

Claims (24)

1. A method of treating a patient suffering from cardiac electrical storm, comprising:

identifying or selecting a patient who has suffered from or is at risk of suffering from cardiac electrical storm or one or more episodes of cardiac arrhythmia; and

administering a composition of bupivacaine multivesicular liposomes (MVLs) to one or more nerves of stellate ganglion of the patient, or an autonomic tissue area peripheral to the stellate ganglion, wherein the composition comprises about 20 mg to about 100 mg bupivacaine;

wherein the administering of bupivacaine MVLs provides relief of cardiac electrical storm for 2 weeks and up to 6 months, and temporarily reduces or interrupts sympathetic stimulation to the cardiovascular system for 2 weeks and up to 6 months.

2. The method of claim 1 , wherein the patient has suffered from or is at risk of suffering from ventricular arrhythmia, ventricular tachycardia, ventricular fibrillation, refractory ventricular arrhythmia, refractory ventricular tachycardia, or refractory ventricular fibrillation.

3. The method of claim 1 , wherein the patient has an implantable cardioverter-defibrillator (ICD) or had a heart surgery.

4. The method of claim 1 , wherein the concentration of bupivacaine in the composition is about 13.3 mg/mL.

5. The method of claim 1 , wherein the composition comprises from about 25 mg to about 75 mg bupivacaine.

6. The method of claim 1 , wherein the total volume of the composition administered is from about 3 mL to about 20 mL.

7. The method of claim 6 , wherein the total volume of the composition administered is from about 5 mL to about 10 mL for unilateral stellate ganglion block.

8. The method of claim 6 , wherein the total volume of the composition administered is from about 10 mL to about 20 mL for bilateral stellate ganglion block.

9. The method of claim 1 , wherein the bupivacaine is in the form of bupivacaine phosphate.

10. The method of claim 1 , wherein the administrating of the composition of bupivacaine MVLs comprises:

navigating a treatment apparatus to stellate ganglion of the patient, or an autonomic tissue area peripheral to the stellate ganglion, wherein the treatment apparatus comprises a needle and a compartment for the composition of bupivacaine MVLs;

injecting the bupivacaine MVLs from the treatment apparatus to the one or more nerves of the stellate ganglion, or the autonomic tissue area peripheral to the stellate ganglion; and

removing the treatment apparatus from the patient.

11. The method of claim 10 , wherein navigating the treatment apparatus to the stellate ganglion comprises inserting the needle of the treatment apparatus percutaneously to the one or more nerves of the stellate ganglion, or the autonomic tissue area peripheral to the stellate ganglion.

12. The method of claim 10 , wherein navigating the treatment apparatus to the stellate ganglion comprises guiding the needle using an imaging guide.

13. The method of claim 12 , wherein the imaging guide comprises a fluoroscopic or an ultrasound imaging guide.

14. The method of claim 10 , wherein the injection comprises bolus injection, continuous infusion, or a combination thereof.

15. The method of claim 10 , wherein the administering is to the left stellate ganglion or to both the left and the right stellate ganglion.

16. The method of claim 10 , wherein the one or more nerves of the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion comprise one or more nerves of both the left and the right stellate ganglion, or one or more nerves of the left stellate ganglion.

17. The method of claim 10 , wherein the one or more nerves of the stellate ganglion or the autonomic tissue area peripheral to the stellate ganglion comprise one or more nerves of a paravertebral chain.

18. The method of claim 17 , wherein the one or more nerves of the paravertebral chain comprises one or more nerves of a C7 region of the paravertebral chain, a C8 region of the paravertebral chain, a T1 region of the paravertebral chain, or combinations thereof.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Dec 5, 2025
From: JPMORGAN CHASE BANK, N.A.
To: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.)
Reel/Frame 073779/0532 →
SECURITY INTEREST Recorded Jul 4, 2025
From: PACIRA PHARMACEUTICALS, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 071814/0792 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 30, 2024
From: SPRANGER, JOHN; WINSTON, ROY; HAM, JARED; SLONIN, JONATHAN
To: PACIRA PHARMACEUTICALS, INC.
Reel/Frame 068129/0609 →
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Mar 31, 2023
From: PACIRA CRYOTECH, INC.; PACIRA PHARMACEUTICALS, INC.; PACIRA THERAPEUTICS, INC. (F/K/A FLEXION THERAPEUTICS, INC.)
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 063214/0108 →
Continuity (2)
Provisional Application 63313691 · Feb 24, 2022
Related Publication 20230277516A1 · Sep 7, 2023
References Cited (30)
US 6045824A · Kim et al. · 2000 [cited by applicant]
US 11033495B1 · Hall et al. · 2021 [cited by applicant]
US 20020039596A1 · Hartounian et al. · 2002 [cited by applicant]
US 20240156799A1 · Spranger · 2024 [cited by applicant]
WO WO99013865 · 1999 [cited by applicant]
WO WO21141959 · 2021 [cited by applicant]
Tian et al., Effective Use of Percutaneous Stellate Ganglion Blockade in Patients with Electrical Storm, Circulation: Arrhythmia and Electrophysiology, 12, p. 1-9. (Year: 2019). [cited by examiner]
Qureshi et al., Long Acting Liposomal Bupivacaine for Percutaneous Sympathetic Stellate Ganglion Blockade: a Technical Note, Journal of Vascular and Interventional Neurology, 9, p. 49-53. (Year: 2017). [cited by examiner]
Davidson et al., High-Dose Bupivacaine Remotely Loaded into Multivesicular Liposomes Demonstrates Slow Drug Release Without Systemic Toxic Plasma Concentrations After Subcutaneous Administration in Humans, International… [cited by examiner]
Kim et al. A Prospective, Randomized Cross-Over Trial of T2 Paravertebral Block as a Sympathetic Block in Complex Regional Pain Syndrome, Pain Physician, 22: E417-E424. (Year: 2019). [cited by examiner]
Tighe et al. Paravertebral block (Continuing Education in Anaesthesia, Critical Care & Pain, 10:5, 133-137). (Year: 2010). [cited by examiner]
Abrich et al., Jan. 10, 2017, Left Stellate Ganglion Block: Increasing Clinician Awareness in the Eye of the Electrical Storm, American College of Cardiology, vol. 76. Retrieved from the Internet: URL:https://www.acc.or… [cited by applicant]
Davidson et al., 2010, High-Dose Bupivacaine Remotely Loaded into Multivesicular Liposomes Demonstrates Slow Drug Release Without Systemic Toxic Plasma Concentrations After Subcutaneous Administration in Humans, Anesthe… [cited by applicant]
Ferrillo, 2016, Treatment of complex regional pain syndrome with stellate ganglion local anesthetic blockade: a case report of one patient's experiences with traditional bupivacaine HCI and liposome bupivacaine, Clinica… [cited by applicant]
García-Morán et al., 2016, Refractory Electrical Storm: A Role for Transient Sympathetic Blockade, Rev. Esp. Cardiol., 69(1):75-85. [cited by applicant]
Hayase et al., Aug. 2013, Percutaneous stellate ganglion block suppressing VT and VF in a patient refractory to VT ablation, J. Cardiovasc Electrophysiol., 24(8): doi:10.1111/jce. 12138, 6 pp. [cited by applicant]
Kowlgi et al., 2020, Management of ventricular electrical storm: a contemporary appraisal, Europace, 22:1768-1780. [cited by applicant]
Malik et al., 2017, Emerging roles of liposomal bupivacaine in anesthesia practice, Journal of Anaesthesiology Clinical Pharmacology, 33:151-156. [cited by applicant]
Meng et al., 2017, Efficacy of Stellate Ganglion Blockade in Managing Electrical Storm: A Systematic Review, JACC Clinical Electrophysiology, 3(9):942_949. [cited by applicant]
Naseem et al., 2012, Bupivacaine Extended Release Liposome Injection Does Not Prolong QTc Interval in a Thorough QT/QTc Study in Healthy Volunteers, Journal of Clinical Pharmacology, 52:1441-1447. [cited by applicant]
Qureshi et al., 2017, Long Acting Liposomal Bupivacaine for Percutaneous Sympathetic Stellate Ganglion Blockade: A Technical Note, Journal of Vascular and Interventional Neurology, 9(5):49-53. [cited by applicant]
Tian et al., 2019, Effective Use of Percutaneous Stellate Ganglion Blockade in Patients With Electrical Storm, Circulation: Arrhythmia and Electrophysiology, 12:e007118, pp. 1-9. [cited by applicant]
International Search Report and Written Opinion dated Apr. 12, 2023 in International Application No. PCT/US2023/062936. [cited by applicant]
Bramlett et al., Dec. 1, 2015, Long-Term Consequences of Traumatic Brain Injury: Current Status of Potential Mechanisms of Injury and Neurological Outcomes, J. Neurotrauma, 32:183401848. [cited by applicant]
Bryant, Oct. 2019, Post-traumatic stress disorder: a state-of-the-art review of evidence and challenges, World Psychiatry 18:259-269. [cited by applicant]
Chan et al., 2010, A case of sympathetically mediated headache treated with stellate ganglion blockade, Pain Med. 11:1294-1298. [cited by applicant]
Deng et al., Apr. 6, 2023, Treatment of stellate ganglion block in diseases: Its role and application prospect, World J Clin Cases, 11(10):2160-2167. [cited by applicant]
Hutchins et al., Oct. 2018, Ultrasound-guided stellate ganglion block with liposome bupivacaine for malignant ventricular arrhythmia: a case report, Regional Anesthesia and Pain Medicine, 43(7):Supplement 1, e68. [cited by applicant]
Nampiaparampil, Aug. 13, 2008, Prevalence of chronic pain after traumatic brain injury: a systematic review, JAMA, 300(6):711-719. [cited by applicant]
Pavlovic et al., 2019, Traumatic brain injury: neuropathological, neurocognitive and neurobehavioral sequelae, Pituitary, 22:270-282. [cited by applicant]